[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494707":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":18,"id":57,"slug":18,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Rabin Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tissue adhesive","EXPERIMENTAL","Tissue adhesive application at the CVL exit-site, on all CVLs, PICCs during the patient LOS. Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine \\>2mo).",[13],"Device: 2-octyl cyanoacrylate based topical skin adhesive",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine \\>2mo).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","2-octyl cyanoacrylate based topical skin adhesive","Tissue adhesive on CVL exit-site",[9],[26],{"name":27,"affiliation":28,"role":29},"Ovadia Dagan, Prof. M.D","Director PCICU, Schneider Children's Medical Center","STUDY_DIRECTOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Eran Shostak, MD","CONTACT","972-3-9253114","eransho@clalit.org.il",[37],{"facility":38,"status":39,"city":40,"state":18,"zip":18,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Schneider's children medical center","RECRUITING","Petah Tikva","Israel",{"type":43,"coordinates":44},"Point",[45,46],34.88747,32.08707,{"lat":46,"lon":45},[49,50],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},{"name":51,"role":52,"phone":18,"phoneExt":18,"email":18},"Ofer Schiller, M.D","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","ERAN SHOSTAK","Principal Investigator","100494707",false,"NCT05721677","CLABSI Prevention With Tissue Adhesive","The Impact of Central-line Exit-site Sealing With 2-octyl Cyanoacrylate Adhesive on CLABSI in Pediatric Cardiac Intensive Care Unit","Cya-No-CLABSI","Inclusion Criteria:\n\nAll patients admitted to pediatric cardiac ICU (PCICU) defined as high-risk for CLABSI (any of):\n\n* young age\\\u003C1y \\& Congenital Heart Surgery Mortality Category (STAT\\\\STS-EACTS) score 2-5\n* Risk Adjustment for Congenital Heart Surgery (RACHS) category ≥3\n* preoperative length-of-stay (LOS) \\>7 days\n* preoperative ventilator support\n* presence of a genetic abnormality\n* extracorporeal membrane oxygenation (ECMO) support\n\nExclusion Criteria:\n\n* Patients with on-going bacteremia\n* patients with pre-existing central-line or peripherally inserted central catheter (PICC)\n* parental refusal to participate.","ALL","0 Days","18 Years",{"count":68,"type":69},600,"ESTIMATED","INTERVENTIONAL",[72],"NA","Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.",[75],"Central-line Associated Blood Stream Infections (CLABSI)",[77,78,79,80,81],"CLABSI","Pediatric","Cardiac intensive care","cyanoacrylate","tissue adhesive","2024-09-30",{"date":84,"type":85},"2024-10-02","ACTUAL",{"date":87,"type":85},"2023-03-15",{"date":89,"type":69},"2026-09-15",{"name":5,"class":6},1]